Novavax Inc. (NVAX) on Wednesday said that the postmarketing commitment study for its COVID-19 vaccine Nuvaxovid will not ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

On Wednesday, Novavax Inc. (NASDAQ:NVAX) reported second-quarter 2025 sales of $239.24 million, compared to $415 million a year ago, beating the consensus of $156.29 million. The company completed the ...

Novavax NVAX reported second-quarter 2025 earnings per share (EPS) of 62 cents against the Zacks Consensus Estimate of a loss of seven cents per share. However, the reported figure declined 37% year ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

(Reuters) -Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone ...

Sanofi made an up-front payment of $500 million to Novavax. In exchange, the France-based biotech obtained the right to commercialize Nuvaxovid, Novavax's COVID vaccine, in most countries worldwide.

Nuvaxovid sales reached $608 million, up from $82 million a year ago. Cost of sales for the first quarter of 2025 was $14 million, compared to $59 million in the same period in 2024.

In Europe, Nuvaxovid sales shot up to $90.4 million during the first quarter, which is already high enough to justify the present valuation of Novavax stock. Sanofi expects to begin recording ...

Sanofi will pay $500 million up front to Novavax for the right to co-commercialize Nuvaxovid worldwide (except in a few select countries).